Diagnosis and Management of Generalized Joint Hypermobility
Use the 2017 International Consensus diagnostic criteria with the Beighton score as your primary screening tool, followed by systematic assessment of connective tissue manifestations and mandatory genetic testing to exclude alternative diagnoses before confirming hypermobile Ehlers-Danlos syndrome (hEDS). 1
Diagnostic Approach
Step 1: Screen with the Beighton Score
The Beighton scoring system evaluates five specific maneuvers, awarding points for bilateral findings where applicable (maximum 9 points): 1
- Fifth finger (pinky) passive dorsiflexion beyond 90° (1 point per side)
- Thumb passive apposition to the forearm (1 point per side)
- Elbow hyperextension beyond 10° (1 point per side)
- Knee hyperextension beyond 10° (1 point per side)
- Forward spinal flexion with palms flat on floor without knee bending (1 point) 2
Age-specific thresholds for positive screening: 1
- Pre-pubertal children: ≥6/9 points
- Puberty through age 50: ≥5/9 points
- Age ≥50 years: ≥4/9 points
Step 2: Assess for Connective Tissue Manifestations
If the Beighton score is positive, evaluate for at least two of the following features to meet criterion 2: 1
- Skin findings: soft velvety texture, hyperextensibility, unexplained striae, or atrophic scarring
- Musculoskeletal symptoms: chronic joint pain (≥3 months duration) affecting multiple joints, plus recurrent dislocations or subluxations
- Pelvic floor dysfunction: including rectal or uterine prolapse
- Family history: first-degree relative meeting full hEDS criteria
Step 3: Exclude Alternative Diagnoses Through Genetic Testing
This step is mandatory and non-negotiable. 1 Genetic testing identified alternative or additional diagnoses in 26.4% of patients who initially appeared to meet hEDS criteria, with direct implications for management. 3 The molecular basis for hEDS remains unknown, making exclusion of other genetic connective tissue disorders essential before confirming the diagnosis. 1, 3
Diagnostic Outcomes
- hEDS diagnosis: All three criteria met (positive Beighton score, ≥2 connective tissue features, alternative diagnoses excluded)
- Hypermobility Spectrum Disorder (HSD): Joint hypermobility with musculoskeletal manifestations but not meeting full hEDS criteria 4, 5
- Asymptomatic joint hypermobility: Positive Beighton score without associated symptoms 5
Screening for Associated Conditions
When to Evaluate for POTS
Screen for postural orthostatic tachycardia syndrome (POTS) only in patients reporting orthostatic symptoms (palpitations, lightheadedness, fatigue, blurred vision, cognitive dysfunction, or gastrointestinal symptoms). 1 POTS affects 37.5% of hEDS patients and significantly increases gastrointestinal dysmotility risk. 1
Diagnostic criteria for POTS: 2, 1
- Heart rate increase ≥30 bpm in adults (≥40 bpm in adolescents 12-19 years) within 10 minutes of standing
- No orthostatic hypotension present
- Symptoms present ≥6 months
- Exclusion of dehydration, medications, primary anxiety disorder, or other medical causes
When to Evaluate for MCAS
Limit mast cell activation syndrome (MCAS) testing to patients with multisystem symptoms (affecting ≥2 organ systems) triggered by specific stimuli such as foods, heat, emotions, or mechanical triggers. 1 Universal screening is not supported by current evidence. 1
Gastrointestinal Considerations
More than 60% of hEDS patients report gastrointestinal symptoms, with 98% meeting criteria for disorders of gut-brain interaction. 1 Gastroenterologists should incorporate Beighton scoring into practice when evaluating patients with these disorders. 2
Treatment Strategy
Primary Intervention: Physical Therapy
Therapeutic exercise and motor function training are the most efficacious treatments for generalized hypermobility spectrum disorder and hEDS. 6 The focus should be on strengthening periarticular muscles to improve joint stability and proprioception. 4
Physical therapy components with evidence support: 6
- Therapeutic exercise (strongest evidence)
- Motor function training (strongest evidence)
- Patient instruction
- Adaptive equipment
- Manual therapy (weak evidence)
- Functional training (weak evidence)
Pharmacologic Management
Use analgesics judiciously and avoid opioids. 4 The medication hierarchy is:
- First-line: NSAIDs and acetaminophen for acute pain episodes 4
- Second-line: Serotonin-norepinephrine reuptake inhibitors (SNRIs) for widespread chronic pain 4
- Avoid: Opioid medications due to chronic pain syndrome nature 4
Lifestyle Modifications
- Weight loss if overweight (reduces joint stress) 4
- Regular exercise program focused on joint stabilization 4
- Activity modification to avoid repetitive joint trauma 7
Critical Pitfalls to Avoid
Do not diagnose hEDS without completing genetic testing. One in four patients initially meeting clinical criteria will have an alternative genetic diagnosis requiring different management. 3
Do not universally screen for POTS or MCAS. Testing should be symptom-driven, not routine. 1
Do not assume asymptomatic hypermobility is benign long-term. Even asymptomatic joint hypermobility can cause repetitive use injury, alter biomechanics, or become symptomatic later in life, warranting patient education about joint protection. 7
Do not overlook the psychological impact. Recent evidence emphasizes the need for multidisciplinary care that addresses both physical and psychological manifestations. 6